New Drug Pathway Must Weigh Risk, Off-Label Use, FDA Hears

Law360, New York (February 4, 2013, 6:24 PM EST) -- A U.S. Food and Drug Administration panel Monday weighed competing visions of a proposed approval pathway for pharmaceuticals targeting unmet medical needs, with advocates for drugmakers, doctors and patients debating appropriate limits on off-label use and asking the agency how risky medications can be.

The hearing stemmed from a September recommendation by the President's Council of Advisors on Science and Technology that the FDA consider approving new therapies for serious and life-threatening illnesses based on relatively small clinical trials focusing on the sickest patients.

Andrew J....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.